Study Of Adults And Adolescents With Vasomotor Rhinitis

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Rhinitis, Vasomotor

Treatments: Drug: GW685698X

Study type: Interventional

Funder types: Industry

Identifiers

NCT00117325

FFR30006

Details and patient eligibility

About

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

Enrollment: 352 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be outpatients.
• Diagnosis of VMR.
• Literate in English or native language.

Exclusion criteria

• Significant concomitant medical condition.
• Use corticosteroids or other allergy medications during the study.
• Used tobacco products within the past year.

Trial design

352 participants in 1 patient group

GW685698X

Experimental group

Description:

GW685698X

Treatment:

Drug: GW685698X